LY2584702 Tosylate

Catalog No.S7704 Batch:S770403

Print

Technical Data

Formula

C28H27F4N7O3S
Molecular Weight 617.62 CAS No. 1082949-68-5
Solubility (25°C)* In vitro DMSO 25 mg/mL (40.47 mM)
Water Insoluble
Ethanol Insoluble
In vivo (Add solvents to the product individually and in order)
Clear solution
5%DMSO 40%PEG300 5%Tween80 50%ddH2O
0.625mg/ml Taking the 1 mL working solution as an example, add 50 μL of 12.5 mg/ml clarified DMSO stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to clarify; then continue to add 500 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results. 
Clear solution
5% DMSO 95% Corn oil
1.25mg/ml Taking the 1 mL working solution as an example, add 50 μL of 25 mg/ml clear DMSO stock solution to 950 μL of corn oil and mix evenly. The mixed solution should be used immediately for optimal results. 
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description LY2584702 Tosylate is a selective, ATP-competitive p70S6K inhibitor with IC50 of 4 nM. Phase 1.
Targets
p70S6K [1]
(Cell-free assay)
4 nM
In vitro In HCT116 colon cancer cells, LY2584702 inhibits phosphorylation of the S6 ribosomal protein (pS6) with IC50 of 0.1-0.24 μM. [1] LY2584702 has significant synergistic effects when combined with EGFR inhibitor erlotinib or with the mTOR inhibitor everolimus. [2]
In vivo LY2584702 (12.5 mg/kg BID), demonstrates significant antitumor efficacy in both U87MG glioblastoma and HCT116 colon carcinoma xenograft models. [1]

Protocol (from reference)

Animal Study:

[1]
  • Animal Models

    U87MG glioblastoma and HCT116 colon carcinoma xenograft models

  • Dosages

    12.5 mg/kg BID

  • Administration

    --

Customer Product Validation

Data from [Data independently produced by , , PLoS One, 2017, 12(1):e0169804]

Selleck's LY2584702 Tosylate has been cited by 18 publications

Deep PIM kinase substrate profiling reveals new rational cotherapeutic strategies for acute myeloid leukemia [ Blood Adv, 2024, 8(15):3880-3892] PubMed: 38739710
Nutrient-regulated control of lysosome function by signaling lipid conversion [ Cell, 2023, 186(24):5328-5346.e26] PubMed: 37883971
Nutrient-regulated control of lysosome function by signaling lipid conversion [ Cell, 2023, 10.1016/j.cell.2023.09.027] PubMed: 37883971
Direct control of lysosomal catabolic activity by mTORC1 through regulation of V-ATPase assembly [ Nat Commun, 2022, 13(1):4848] PubMed: 35977928
Sustained oncogenic signaling in the cytostatic state enables targeting of non-proliferating persistent cancer cells [ Cancer Res, 2022, can.21.2908] PubMed: 35792658
P311 Facilitates the Angiogenesis and Wound Healing Function of MSCs by Increasing VEGF Production [ Front Immunol, 2022, 13:821932] PubMed: 35154140
Differential expression of gene co-expression networks related to the mTOR signaling pathway in bipolar disorder [ Transl Psychiatry, 2022, 12(1):184] PubMed: 35508467
B-cell receptor signaling induces proteasomal degradation of PDCD4 via MEK1/2 and mTORC1 in malignant B cells [ Cell Signal, 2022, 94:110311] PubMed: 35306137
Inhibition of RPS6K reveals context-dependent Akt activity in luminal breast cancer cells [ PLoS Comput Biol, 2021, 17(6):e1009125] PubMed: 34191793
Selective abrogation of S6K2 maps lipid homeostasis as a survival vulnerability in MAPKi-resistant NRASMUT melanoma [ bioRxiv, 2021, 10.1101/2021.04.07.438684] PubMed: none

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.